NZ515248A - Heterocyclic substituted carboxylic acid derivatives useful for inhibit the binding of integrins to their receptors - Google Patents

Heterocyclic substituted carboxylic acid derivatives useful for inhibit the binding of integrins to their receptors

Info

Publication number
NZ515248A
NZ515248A NZ515248A NZ51524800A NZ515248A NZ 515248 A NZ515248 A NZ 515248A NZ 515248 A NZ515248 A NZ 515248A NZ 51524800 A NZ51524800 A NZ 51524800A NZ 515248 A NZ515248 A NZ 515248A
Authority
NZ
New Zealand
Prior art keywords
alkyl
nhc
carboxylic acid
binding
integrins
Prior art date
Application number
NZ515248A
Other languages
English (en)
Inventor
Ronald J Biediger
Qi Chen
George W Holland
Jamal M Kassir
Wen Li
Robert V Market
Ian L Scott
Chengde Wu
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of NZ515248A publication Critical patent/NZ515248A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ515248A 1999-05-07 2000-05-05 Heterocyclic substituted carboxylic acid derivatives useful for inhibit the binding of integrins to their receptors NZ515248A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13297199P 1999-05-07 1999-05-07
PCT/US2000/012303 WO2000067746A1 (en) 1999-05-07 2000-05-05 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Publications (1)

Publication Number Publication Date
NZ515248A true NZ515248A (en) 2004-01-30

Family

ID=22456441

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515248A NZ515248A (en) 1999-05-07 2000-05-05 Heterocyclic substituted carboxylic acid derivatives useful for inhibit the binding of integrins to their receptors

Country Status (23)

Country Link
EP (1) EP1176956B1 (enExample)
JP (1) JP5132855B2 (enExample)
AT (1) ATE383153T1 (enExample)
AU (1) AU5267900A (enExample)
CA (1) CA2373360C (enExample)
CY (1) CY1107438T1 (enExample)
CZ (1) CZ303312B6 (enExample)
DE (1) DE60037726T2 (enExample)
DK (1) DK1176956T3 (enExample)
ES (1) ES2296625T3 (enExample)
IL (2) IL146311A0 (enExample)
IN (1) IN2001KN01110A (enExample)
MX (1) MXPA01011340A (enExample)
NO (1) NO324421B1 (enExample)
NZ (1) NZ515248A (enExample)
PL (1) PL205322B1 (enExample)
RO (1) RO122246B1 (enExample)
RU (1) RU2263109C2 (enExample)
SI (1) SI20744B (enExample)
SK (1) SK286696B6 (enExample)
TR (2) TR200201920T2 (enExample)
WO (1) WO2000067746A1 (enExample)
ZA (1) ZA200108774B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
AP1822A (en) * 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
PE20040728A1 (es) 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
CN1735601A (zh) * 2002-11-08 2006-02-15 先灵公司 抑制整联蛋白与其受体结合的羧酸衍生物和其它治疗化合物的组合产物
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
WO2005014532A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
CA2680366C (en) * 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
WO2009015485A1 (en) 2007-08-01 2009-02-05 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
SG10201401836RA (en) * 2009-04-27 2014-10-30 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
US8952024B2 (en) * 2009-09-09 2015-02-10 E I Du Pont De Nemours And Company Herbicidal pyrimidone derivatives
WO2012033548A2 (en) * 2010-09-07 2012-03-15 E. I. Du Pont De Nemours And Company Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles
SG11201404505PA (en) * 2012-01-31 2014-10-30 Daiichi Sankyo Co Ltd Pyridone derivative
CN110372636B (zh) 2013-09-20 2023-03-28 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
US20170002077A1 (en) 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) * 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
EP3615087B1 (en) * 2017-04-28 2023-09-06 Texas Children's Hospital Targeting nanoparticles
PL3746441T3 (pl) * 2018-02-02 2023-07-31 Genentech, Inc. Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614189A1 (de) * 1976-04-02 1977-10-20 Hoechst Ag Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
DE69425431T2 (de) * 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
US5534529A (en) * 1993-06-30 1996-07-09 Sankyo Company, Limited Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JPH07304755A (ja) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
US5610296A (en) * 1994-12-05 1997-03-11 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP0912901B1 (en) * 1996-05-15 2001-11-07 G.D. Searle & Co. Method and reagent for monitoring blood levels of antiplatelet compounds
CA2265827A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
HK1040076A1 (zh) * 1998-09-21 2002-05-24 希雷生物化学有限公司 作为整联蛋白抑制剂的喹嗪酮

Also Published As

Publication number Publication date
CZ303312B6 (cs) 2012-07-25
WO2000067746A1 (en) 2000-11-16
EP1176956B1 (en) 2008-01-09
TR200103178T2 (tr) 2002-05-21
CY1107438T1 (el) 2012-12-19
IL146311A (en) 2011-10-31
PL205322B1 (pl) 2010-04-30
WO2000067746A9 (en) 2002-08-29
DE60037726T2 (de) 2009-03-05
SI20744A (sl) 2002-06-30
ATE383153T1 (de) 2008-01-15
IN2001KN01110A (enExample) 2015-06-05
NO20015418L (no) 2001-12-21
EP1176956A1 (en) 2002-02-06
RO122246B1 (ro) 2009-03-30
MXPA01011340A (es) 2003-08-01
SI20744B (sl) 2009-08-31
JP5132855B2 (ja) 2013-01-30
CA2373360C (en) 2011-09-06
SK286696B6 (sk) 2009-03-05
RU2263109C2 (ru) 2005-10-27
JP2002544161A (ja) 2002-12-24
ES2296625T3 (es) 2008-05-01
IL146311A0 (en) 2002-07-25
NO20015418D0 (no) 2001-11-06
CA2373360A1 (en) 2000-11-16
DE60037726D1 (de) 2008-02-21
SK16082001A3 (sk) 2002-04-04
DK1176956T3 (da) 2008-05-26
EP1176956A4 (en) 2002-08-28
WO2000067746A8 (en) 2002-02-28
NO324421B1 (no) 2007-10-08
PL351396A1 (en) 2003-04-07
ZA200108774B (en) 2003-01-24
HK1045805A1 (en) 2002-12-13
TR200201920T2 (tr) 2002-09-23
AU5267900A (en) 2000-11-21
CZ20013963A3 (cs) 2002-04-17

Similar Documents

Publication Publication Date Title
RU2401260C2 (ru) Пиримидиновые производные
CA2373360A1 (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
EP2053041A3 (en) 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease
EP1338595A3 (en) Xanthine derivatives as DPP-IV inhibitors
DE69735108D1 (de) A-1-adenosin rezeptor antagoniste
CA2334399A1 (en) Uracil compounds and use thereof
NO20024741L (no) 8-quinolinxantin og 8-isoquinolinxantinderivater som PDE5- inhibitorer
KR960701018A (ko) 제초성의 헤테로사이클릭-치환된 피리딘(Herbicidal heterocyclic-substituted pyridines)
EP1063228A4 (en) CYCLOALCENE DERIVATIVES, THEIR MANUFACTURING METHOD AND THE USE THEREOF
EP0318235A3 (en) Paf antagonist, 1,4-disubstituted piperazine compounds and production thereof
NO990673D0 (no) Purinderivater og deres anvendelse som antikoagulanter
SI20876B (sl) Derivati propanojske kisline, ki inhibirajo vezavo integrinov na njihove receptorje
CA2192824A1 (en) Pyridone-carboxylic acid derivatives, processes for the preparation thereof and anti-tumor agents containing the pyridone-carboxylic acid derivatives
GR3034839T3 (en) Inhibitors and substrates of thrombin.
EP1384717A3 (en) Tetrazolylphenylboronic acid intermediates for the synthesis of A II receptor antagonists
WO2002085928A3 (fr) Cyclosporine modifiee utilisable en tant que pro-drogue et son utilisation
RU98117621A (ru) Новые производные пиперазина и пиперидина, способ их получения, фармкомпозиция на их основе, способ лечения, промежуточный продукт
EP1231208A3 (en) 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents
JP2002522385A5 (enExample)
MX9600347A (es) Pirimidinas 2,6-disubstituidas y pirimidinas 2,4-disubstituidas, su preparacion y su uso como herbicidas.
HUP0100453A1 (hu) Eljárás izokarbamidok előállítására
KR840006342A (ko) 복소환식 화합물 및 그 제법
EA199700313A1 (ru) ПРОИЗВОДНЫЕ β-МЕТОКСИАКРИЛОВОЙ КИСЛОТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ПЕСТИЦИДНАЯ, ИНСЕКТИЦИДНАЯ, АКАРИЦИДНАЯ И ФУНГИЦИДНАЯ КОМПОЗИЦИИ
DE69725167D1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
CO5231148A1 (es) Compuesros herbicidas derivados de la piridina-2,6- sustituida, procedimiento para prepararlos, las composiciones herbicidas que los contienen, el procedimiento de aplicacion de dichos compuestos y el uso de los mismos como herbicidas

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 05 MAY 2020 BY THOMSON REUTERS

Effective date: 20130514

EXPY Patent expired